Technical comment on: Rachamin et al. Statin treatment and LDL target value achievement in Swiss general practice – a retrospective observational study

Michel Romanens; Edward A. Schober; Ansgar Adams; Sandor Balint; Walter Warmuth

doi:10.4414/smw.2020.20373

Technical comment

Vol. 150 No. 4748 (2020)

Technical comment on: Rachamin et al. Statin treatment and LDL target value achievement in Swiss general practice – a retrospective observational study

Michel Romanens⁺⁻
Edward A. Schober⁺⁻
Ansgar Adams⁺⁻
Sandor Balint⁺⁻
Walter Warmuth⁺⁻

Cite this as:: Swiss Med Wkly. 2020;150:w20373
Published: 23.11.2020

References

Rachamin Y, Meier R, Rosemann T, Langenegger S, Markun S. Statin treatment and LDL target value achievement in Swiss general practice - a retrospective observational study. Swiss Med Wkly. 2020;150(2122):w20244. doi:.https://doi.org/10.4414/smw.2020.20244
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. doi:.https://doi.org/10.1093/eurheartj/ehz455
Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al.; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003. doi:.https://doi.org/10.1016/S0195-668X(03)00114-3
Romanens M, Szucs T, Sudano I, Adams A. Agreement of PROCAM and SCORE to assess cardiovascular risk in two different low risk European populations. Prev Med Rep. 2019;13:113–7. doi:.https://doi.org/10.1016/j.pmedr.2018.11.019
Romanens M, Sudano I, Szucs T, Adams A. Medical costs per QALY of statins based on Swiss Medical Board assumptions. Cardiovasc Med. 2017;17(4):96–100. doi:.https://doi.org/10.4414/cvm.2017.0047
Felder S, Jüni P, Meier CA, et al. SMB Statin Recommendation [Internet]. 2014. Available from: https://www.swissmedicalboard.ch/fileadmin/public/news/2013/bericht_smb_statine_primaerpraevention_lang_2013.pdf

How to Cite

1.

Technical comment on: Rachamin et al. Statin treatment and LDL target value achievement in Swiss general practice – a retrospective observational study. Swiss Med Wkly [Internet]. 2020 Nov. 23 [cited 2025 Oct. 28];150(4748):w20373. Available from: https://smw.ch/index.php/smw/article/view/2905

Share

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

DOI:: https://doi.org/10.4414/smw.2020.20373

[1] Rachamin Y, Meier R, Rosemann T, Langenegger S, Markun S. Statin treatment and LDL target value achievement in Swiss general practice - a retrospective observational study. Swiss Med Wkly. 2020;150(2122):w20244. doi:.https://doi.org/10.4414/smw.2020.20244

[2] Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. doi:.https://doi.org/10.1093/eurheartj/ehz455

[3] Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al.; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003. doi:.https://doi.org/10.1016/S0195-668X(03)00114-3

[4] Romanens M, Szucs T, Sudano I, Adams A. Agreement of PROCAM and SCORE to assess cardiovascular risk in two different low risk European populations. Prev Med Rep. 2019;13:113–7. doi:.https://doi.org/10.1016/j.pmedr.2018.11.019

[5] Romanens M, Sudano I, Szucs T, Adams A. Medical costs per QALY of statins based on Swiss Medical Board assumptions. Cardiovasc Med. 2017;17(4):96–100. doi:.https://doi.org/10.4414/cvm.2017.0047

[6] Felder S, Jüni P, Meier CA, et al. SMB Statin Recommendation [Internet]. 2014. Available from: https://www.swissmedicalboard.ch/fileadmin/public/news/2013/bericht_smb_statine_primaerpraevention_lang_2013.pdf